Results 191 to 200 of about 6,860 (236)
Some of the next articles are maybe not open access.
In Vitro Activity of Doripenem
Clinical Infectious Diseases, 2009Doripenem is a carbapenem antibiotic that covers a wide range of gram-positive and gram-negative pathogens. In vitro studies have provided insight into certain features of doripenem's activity profile that may have particular relevance in the clinical setting.
openaire +2 more sources
Future Microbiology, 2019
Aim: To propose newer combinations of antibiotics effective against NDM-1-producing bacterial strains. Materials & methods: Antibiotics combinations were tested by checkerboard assay.
Lubna Maryam +3 more
semanticscholar +1 more source
Aim: To propose newer combinations of antibiotics effective against NDM-1-producing bacterial strains. Materials & methods: Antibiotics combinations were tested by checkerboard assay.
Lubna Maryam +3 more
semanticscholar +1 more source
Materials letters (General ed.), 2018
In the present study, Janus type Ag: SnO2 heterojunction has been synthesized by a green route and has been utilized as a photocatalyst for the degradation of Doripenem, a prototype for emerging antibiotic pollutant.
D. Mohanta, Sauvik Raha, M. Ahmaruzzaman
semanticscholar +1 more source
In the present study, Janus type Ag: SnO2 heterojunction has been synthesized by a green route and has been utilized as a photocatalyst for the degradation of Doripenem, a prototype for emerging antibiotic pollutant.
D. Mohanta, Sauvik Raha, M. Ahmaruzzaman
semanticscholar +1 more source
Doripenem Versus Bacteria: An Emerging Battleground
Journal of Chemotherapy, 2009Doripenem is a new 1-beta-methyl carbapenem with broad-spectrum activity against clinically important pathogens. Its activity matches imipenem or ertapenem against Gram-positive bacteria and meropenem against Gram-negative bacteria. It may offer slightly more activity than meropenem against selected pathogens.
S, Shakil, M, Danishuddin, A U, Khan
openaire +2 more sources
Drugs, 2008
Doripenem, a parenteral, broad-spectrum antibacterial agent of the carbapenem family, is indicated as empirical therapy in serious bacterial infections in adults. Doripenem is indicated in Japan for use as a single agent in intra-abdominal infections (IAIs), lower respiratory tract infections (including nosocomial pneumonia), complicated urinary tract ...
openaire +2 more sources
Doripenem, a parenteral, broad-spectrum antibacterial agent of the carbapenem family, is indicated as empirical therapy in serious bacterial infections in adults. Doripenem is indicated in Japan for use as a single agent in intra-abdominal infections (IAIs), lower respiratory tract infections (including nosocomial pneumonia), complicated urinary tract ...
openaire +2 more sources
Overview of Seizure-Inducing Potential of Doripenem
Drug Safety, 2009The seizure-inducing potential of carbapenems has been debated since the introduction of imipenem/cilastatin over 20 years ago. Doripenem is a new carbapenem, recently approved in the US for the treatment of adults with complicated urinary tract infections (cUTI) or complicated intra-abdominal infections (cIAI), and additionally in the EU for ...
George G, Zhanel +4 more
openaire +2 more sources
Carbapenems in the USA: focus on doripenem
Expert Review of Anti-infective Therapy, 2007The threat of antibacterial resistance continues to increase globally, and therapeutic options for the treatment of some serious infectious diseases are diminishing. The carbapenems are a potent class of broad-spectrum drugs, and their stability against hydrolysis by many important beta-lactamases make them an important weapon in the treatment of beta ...
openaire +2 more sources
Maculopapular eruption caused by doripenem
European Journal of Dermatology, 2017Doripenem is a carbapenem antibiotic drug with a strong bactericidal activity against many Gram-negative bacteria [1]. While doripenem is widely used for the treatment of various infectious diseases, only one report of drug eruption caused by doripenem has been reported, manifesting with Stevens-Johnson syndrome [2].
Mayu Shibata +7 more
openaire +1 more source
Journal of Pharmacy and Science, 2019
The aims of this study were to evaluate the pharmacokinetics of doripenem (Finibax®, Doribax®, S-4661), a parenteral carbapenem antibiotic, in pediatric patients based on concentrations of doripenem in plasma after administration of 20 mg/kg 2 or 3 times
Yumiko Matsuo +4 more
semanticscholar +1 more source
The aims of this study were to evaluate the pharmacokinetics of doripenem (Finibax®, Doribax®, S-4661), a parenteral carbapenem antibiotic, in pediatric patients based on concentrations of doripenem in plasma after administration of 20 mg/kg 2 or 3 times
Yumiko Matsuo +4 more
semanticscholar +1 more source